Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L, Bertucci F, Tresch-Bruneel E, Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S, Decoupigny E, Blay JY, Goncalves A, Penel N. Lebellec L, et al. Among authors: camoin l. Oncotarget. 2016 Nov 8;7(45):73984-73994. doi: 10.18632/oncotarget.12172. Oncotarget. 2016. PMID: 27659533 Free PMC article.
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC. Lebellec L, et al. Among authors: camoin l. BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1. BMC Cancer. 2018. PMID: 30305054 Free PMC article. Clinical Trial.
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.
Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L. Guerin M, et al. Among authors: camoin l. Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18. Oncotarget. 2018. PMID: 30333908 Free PMC article.
How may targeted proteomics complement genomic data in breast cancer?
Guerin M, Gonçalves A, Toiron Y, Baudelet E, Audebert S, Boyer JB, Borg JP, Camoin L. Guerin M, et al. Among authors: camoin l. Expert Rev Proteomics. 2017 Jan;14(1):43-54. doi: 10.1080/14789450.2017.1256776. Epub 2016 Nov 15. Expert Rev Proteomics. 2017. PMID: 27813428 Review.
Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.
Takedachi A, Despras E, Scaglione S, Guérois R, Guervilly JH, Blin M, Audebert S, Camoin L, Hasanova Z, Schertzer M, Guille A, Churikov D, Callebaut I, Naim V, Chaffanet M, Borg JP, Bertucci F, Revy P, Birnbaum D, Londoño-Vallejo A, Kannouche PL, Gaillard PHL. Takedachi A, et al. Among authors: camoin l. Nat Struct Mol Biol. 2020 Jun;27(6):604. doi: 10.1038/s41594-020-0447-z. Nat Struct Mol Biol. 2020. PMID: 32409716
Author Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.
Takedachi A, Despras E, Scaglione S, Guérois R, Guervilly JH, Blin M, Audebert S, Camoin L, Hasanova Z, Schertzer M, Guille A, Churikov D, Callebaut I, Naim V, Chaffanet M, Borg JP, Bertucci F, Revy P, Birnbaum D, Londoño-Vallejo A, Kannouche PL, Gaillard PHL. Takedachi A, et al. Among authors: camoin l. Nat Struct Mol Biol. 2020 Jun;27(6):603. doi: 10.1038/s41594-020-0448-y. Nat Struct Mol Biol. 2020. PMID: 32409717
162 results